tbuckley/cabot-search huggingface dataset:
P687Complement system modulation as a target for treatment of arrhythmogenic cardiomyopathy
Authors: M Mavroidis, C Davos, A Varela, I Kostavasili, K Tsilafakis, A Vater, J P Van Tintelen, Y Capetanaki
Journal: Cardiovascular Research (2014)

Objectives, Background: Inflammation may contribute to disease progression in arrhythmogenic cardiomyopathy (AC) however, its role in this process is unresolved. Our goal was to delineate the pathogenic role of the complement system in a new animal model of AC and its involvement in human disease. Methods and Results: By cardiac histology, echocardiography, and electrocardiography we have demonstrated that the desmin-null mouse (Des-/-) recapitulates most of the pathognomonic features of human AC. Massive complement activation was observed in the Des-/- myocardium in areas of necrotic cells debris and inflammatory infiltrate. Analysis of C5aR-/-Des-/- double-null animals and a pharmaceutical approach using the C5a-neutralizing Spiegelmer were used to delineate the pathogenic role of the complement system in the disease progression. Our findings indicate that inhibiting C5aR (CD88) signaling appreciably improves cardiac function, histopathology, and arrhythmias. Containment of the inflammatory reaction at the initiation of cardiac tissue injury (at 2-3 weeks of age) with a consequently reduced myocardial remodelling and the absence of a direct long lasting detrimental effect of C5a-C5aR signaling on cardiomyocytes could explain the beneficial action of C5aR ablation in Des-/- cardiomyopathy. We substantiated the relevance of these findings to human pathophysiology by demonstrating, for the first time, significant complement activation in the cardiac tissues from patients with AC. Conclusions: Complement could be a valid target for treatment/amelioration of AC.
Case 4-1993
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Peter Rubin, Nancy L. Harris
Journal: New England Journal of Medicine (1993)

Presentation of CaseFirst admission. A 73-year-old man was admitted to the hospital because of worsening right upper facial pain and decreasing visual acuity in the right eye.There was a history of Hodgkin's disease localized to the right groin 27 years earlier, which was treated with excisional biopsy and radiation treatment, without a recurrence. More recently, the patient required treatment for primary hypothyroidism, insulin-dependent diabetes mellitus, hypertension, chronic atrial fibrillation, and chronic obstructive pulmonary disease; he had a long history of cigarette smoking until three years before entry. Six years before admission chronic lymphocytic leukemia (CLL), stage 0, was . . .
SAT0417 Cost-Effectiveness of Inpatient and Outpatient Physical Therapy of Patients with Lumbar Intervertebral Disc Herniation
Authors: F. Ö. Özet, D. evcik, S. ay, S. koldaş doğan, S. yüksel
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Low back pain is a common health problem and is quite important because of high costs due to direct and indirect costs for the community (1,2) <h3>Objectives</h3> The aim of this study is to compare cost-effectiveness of inpatient and outpatient physical therapy programs for patients with lumbar intervertebral disc herniation. <h3>Methods</h3> Sixty patients withlumbar intervertebral disc herniation diagnosed by using Magnetic Resonance Imaging were included in the study. Patients were divided into two groups; Group 1 (n=30) received inpatient Physical therapy program (electrotherapy, superficial-deep heat administration and basic lumbar exercise program) and group 2 (n=30) received outpatient physical therapy program (the same treatment schedule). Assessment parameters were pain, functional capacity and quality of life(QoL). Pain intensity, patients' global assesment and doctor's global assessment were measured with visual analog scale (VAS), functional capacity with Rolland Morris disability questionnaire and QoL with short form 36 (SF-36). The expenses spent were calculated as direct health, direct non-health and indirect costs. All expenditures and all measurements were assessed for five times during the entire study: before treatment, just after treatment, and after first, third and sixth months of the treatment. <h3>Results</h3> In our study, we found that out-patient treatment had the the lowest cost compared to inpetient group. The estimated total costs for 6 months of out-patient and in-patient treatments were1.804,330TL (approximately 753.195 EUR) and 3.885,943TL (approximately 1.621,98 EUR) respectively. Total utilities of these treatments were 2,28 and 3,16 respectively. An additional 2.359,179TL (approximately 984 EUR) per one patient were gained compaired to in-patient treatment <h3>Conclusions</h3> This study suggested that physical therapy programs were effective in the treatment of lumbar intervertebral disc herniation. However, inpatient physical therapy program was more cost and more effective than outpatient physical therapy program <h3>References</h3> Critchley DJ, Ratcliffe J, Noonan S, Jones RH, Hurley MV. Effectiveness and cost-effectiveness of three types of physiotherapy used to reduce chronic low back pain disability: a pragmatic randomized trial with economic evaluation. Spine (Phila Pa 1976). 2007 Jun 15;32(14):1474-81. Maas ET, juch JN, Groeneweg JG, Ostelo RW, Koes BW, Verhogen AP, van Raamt M, Wille F, Huygen FJ, van Tulder MW. Cost-effectiveness of minimal interventional procedures for chronic mechanical low back pain: design of four randomized controlled trials with an economic evalution BMJ Musculoskelet disord 2012 Dec 28;13:260 <h3>Disclosure of Interest</h3> None Declared
P120 MODULATION OF NF-κB ACTIVITY BY DCA: EFFECTS ON miR-21, APOPTOSIS AND INFLAMMATION
Authors: P.M. Rodrigues, M.B. Afonso, A.L. Simão, D.M.S. Ferreira, P.M. Borralho, C.M.P. Rodrigues, R.E. Castro
Journal: Journal of Hepatology (2014)
Toll like receptor 3 expression and efficacy of adjuvant treatment with polyadenylic-polyuridylic acid in patients with axillary node positive breast cancer: Results from two randomized trials
Authors: F. André, C. Massard, H. Assi, B. Besse, J. Sabourin, L. Zitvogel
Journal: Journal of Clinical Oncology (2006)

10563 Background: Toll like receptor 3 (TLR3) are transmembrane receptors involved in the cellular response to danger signal and specifically activated by double stranded RNA. Based on these data, we hypothesized that the TLR3 expression by tumor cells is associated with the efficacy of a treatment with double stranded RNA in cancer patients. Patients and Methods: TLR3 expression was assessed by immunohistochemistry in 336 patients with axillary node positive breast cancer. These patients were selected to have been included in two randomized trials that compared a post-operative administration of polyadenylic-polyuridylic acid (polyAU) to either no treatment (n = 174, trial I) or an adjuvant chemotherapy by CMF regimen (n = 162, trial II). In the trial II, locoregional and pelvic radiotherapy were given in the polyAU arm. Results: TLR3 was found to be overexpressed in 45 tumors (13%). Median follow-up were 23 and 17 years for living patients included in the trials I and II respectively. When the analysis focused on the first trial, the 20 year overall survival rates were 87% (95% CI: 53–97%) and 32% (95% CI: 12–63%) for patients with TLR3-overexpressing tumour treated (n = 8) or not (n = 11) with polyAU (p = 0.03). In the same trial, the 20 year overall survival rates were 43% (95% CI: 33–54%) and 35% (95% CI: 25–46%) for patients with TLR3-negative tumor treated (n = 81) or not (n = 74) with polyAU (p = 0.32). When the analysis focused on the Trial II, the 15 year overall survival were 62% (95% CI: 45%-91%) and 21% (95% CI: 8%-47%) for patients with TLR3-overexpressing tumors treated (n = 12) or not (n = 14) with polyAU (p = 0.005). In the same trial, 15 year overall survival rates were 31% (95% CI: 21%-42%) and 39% (95% CI: 28%-51%) for patients with TLR3-negative tumors treated (n = 66) or not (n = 70) with polyAU (p = 0.39). Conclusion: This study suggests that the post-operative administration of polyadenylic-polyuridylic acid improves outcome of patient with TLR3-overexpressing, node-positive breast cancer. [Table: see text]
Abstract 4576: Immunization with CPG in combination with MHC class I and class II peptides stimulates rapid and strong tumor antigen-specific CTL responses in melanoma patients.
Authors: Julien Fourcade, Zhaojun Sun, Ornella Pagliano, Joe-Marc Chauvin, Cindy Sander, Stergios Moschos, Ahmad Tarhini, Hussein Tawbi, John M. Kirkwood, Hassane M. Zarour
Journal: Cancer Research (2013)

Abstract There is now ample evidence that the toll-like receptor 9 ligand CPG/PF-3512676 represents a potent adjuvant for peptide/protein-based cancer vaccines capable of stimulating ex vivo detectable tumor antigen (TA)-specific CD8+ T cell responses in patients with advanced melanoma. Although CD4+ T cells appeared to promote the expansion and functions of CD8+ T cells in experimental models, melanoma-associated helper peptides have been shown to paradoxically decrease CD8+ T cell responses to a multipeptide melanoma vaccine emulsified in Montanide, possibly by inducing antigen-specific Tregs. To further investigate this question, we have performed one Phase I study of immunization where patients with advanced melanoma were immunized with CPG, Montanide and the HLA-A2-restricted analog peptide NY-ESO-1 157-165V either alone (Arm 1, n=5) or in combination with the pan-DR CD4 helper peptide NY-ESO-1 119-143 (Arm 2, n=7). Patients in both arms exhibited a rapid increase of NY-ESO-1-specific CD8+ T cells that were detectable ex vivo by flow cytometry. Strikingly, the mean frequency of vaccine-induced NY-ESO-1-specific CD8+ T cells after 6 biweekly immunizations was five times higher in patients who also received the helper peptide. Melanoma patients immunized with the helper peptide (Arm 2) developed a rapid increase of Foxp3− NY-ESO-1-specific CD4+ T cells that produced Th-1 type cytokines and IL-21 ex vivo. As compared to Arm 1, melanoma patients included in Arm 2 developed vaccine-induced NY-ESO-1-specific CD8+ T cells that were more differentiated, produced more IFN-γ and exhibited higher cytolytic functions in ex vivo assays. Collectively, our data support the inclusion of well-defined MHC class II peptides in combination with CPG/PF-3512676 and MHC class I peptides in multipeptide melanoma vaccines to better augment the expansion, differentiation, IFN-γ production and lytic function of TA-specific CTLs in patients with advanced melanoma. This work was supported by the National Institutes of Health/National Cancer Institute grants R01CA90360 and R01CA157467 (to H.M. Zarour). Citation Format: Julien Fourcade, Zhaojun Sun, Ornella Pagliano, Joe-Marc Chauvin, Cindy Sander, Stergios Moschos, Ahmad Tarhini, Hussein Tawbi, John M. Kirkwood, Hassane M. Zarour. Immunization with CPG in combination with MHC class I and class II peptides stimulates rapid and strong tumor antigen-specific CTL responses in melanoma patients. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4576. doi:10.1158/1538-7445.AM2013-4576
Survey finds that 1 in 10 children has a mental disorder
Authors: G. Yamey
Journal: BMJ (1999)

A survey of the mental health of children in England, Scotland, and Wales has shown that 10% of 5-15 year olds have some type of mental disorder.

The survey was conducted by the Office for National Statistics in partnership with the Institute of Psychiatry and the Maudsley Hospital Researchers interviewed 10500 parents and 4500 children. A postal questionnaire was also sent to the teachers of all children who had …
TREE DERIVED SURVIVAL RISK GROUPS IN DIFFERENTIATING RISK FOR GLIOMA PATIENTS
Authors: A. M. Molinaro, A. Olshen, R. Strawderman
Journal: Neuro-Oncology (2014)

BACKGROUND: We recently developed partDSA, a multivariate method that, similarly to CART, utilizes loss functions to select and partition predictor variables to build a tree-like regression model for a given outcome. However, unlike CART, partDSA permits both 'and' and 'or' conjunctions of predictors, elucidating interactions between variables as well as their independent contributions. partDSA thus permits tremendous flexibility in the construction of predictive models and has been shown to supersede CART in both prediction accuracy and stability. METHODS: With right-censored outcomes, partDSA currently builds estimators via either the Inverse Probability Censoring Weighted (IPCW) or Brier Score weighting schemes; see Lostritto, Strawderman and Molinaro (2012), where it is shown in numerous simulations that both proposed adaptations for partDSA perform as well, and often considerably better, than two competing tree-based methods. RESULTS: We show the power of the partDSA algorithm in deriving survival risk groups for glioma patient based on genomic markers. CONCLUSIONS: As the resulting models take the form of a decision tree, partDSA provides an ideal foundation for developing a clinician-friendly tool for accurate risk prediction and stratification. SECONDARY CATEGORY: Epidemiology & Cancer Control.
Intraoral Presentation of Antrochoanal Polyp
Authors: Afshin Teymoortash
Journal: New England Journal of Medicine (2014)

An otherwise healthy 17-year-old boy presented for evaluation of an incidentally noticed pharyngeal mass. He had no nasal obstruction, rhinorrhea, epistaxis, or postnasal drip. Intraoral examination showed a soft, translucent, round mass in the left pharyngeal area.
REAL-TIME ATLAS-BASED STEREOTACTIC NEURONAVIGATION
Authors: S. Prabhu, M. Vabulas, V. A. Kumar, J. D. Hamilton, J. J. Martinez, G. Rao, R. Sawaya
Journal: Neuro-Oncology (2014)

BACKGROUND: Surgery for tumors in eloquent brain faces immense challenges when attempting to maximize resection and avoid neurological deficits. METHODS: Magnetic resonance imaging (MRI), diffusion tensor imaging, and/or functional MRI were performed on 3 patients preoperatively for the purposes of tumor resection by the use of neuronavigation. The DAT was registered to the patients' navigation coordinate system and utilized coordinates from the navigation system during surgery. This provided the surgeon with a list of proximal anatomic and functional structures and a real-time image of the atlas at that location fused to the patient's MRI. The clinical feasibility of this approach was evaluated during the resection of 3 eloquent tumors (right postcentral gyrus, left inferior frontal gyrus, and left occipital cuneus gyrus). RESULTS: Tumor resection was performed successfully in all 3 patients. With the use of the coordinates from the navigation system, anatomic and functional structures and their distances were visualized interactively during tumor resection by using the DAT. CONCLUSIONS: This is a proof of concept that an interactive atlas-based navigation can provide detailed anatomic and functional information that supplements MRI, diffusion tensor imaging, and functional MRI. The atlas-based navigation generated distances to important anatomic structures from the navigation probe tip. It can be used to guidedirect electrical stimulation and highlight areas to avoid during tumor resection. SECONDARY CATEGORY: Imaging.
Effect of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor on Myelopoiesis in the Acquired Immunodeficiency Syndrome
Authors: Jerome E. Groopman, Ronald T. Mitsuyasu, Michael J. DeLeo, Dagmar H. Oette, David W. Golde
Journal: New England Journal of Medicine (1987)

We administered recombinant (biosynthetic) human granulocyte-macrophage colony-stimulating factor (GM-CSF) to 16 patients with the acquired immunodeficiency syndrome (AIDS) and leukopenia (2225 +/- 614 cells per microliter [mean +/- SD]). Each patient first received a single intravenous dose; 48 hours later a 14-day continuous intravenous infusion of the agent was begun. The doses used were 1.3 X 10(3) (n = 4), 2.6 X 10(3) (n = 4), 5.2 X 10(3) (n = 4), 1.0 X 10(4) (n = 3), or 2.0 X 10(4) (n = 1) U per kilogram of body weight per day. Administration of recombinant GM-CSF resulted in dose-dependent increases in circulating leukocytes and in increases in circulating neutrophils, eosinophils, and monocytes. The peak leukocyte count ranged from 4575 +/- 2397 cells per microliter at the lowest dose, to 48,700 in the patient receiving the highest dose. Mild side effects--low-grade fever, myalgia, phlebitis, and flushing--were observed in some patients; there were no life-threatening toxic reactions. Our data demonstrate that recombinant human GM-CSF is well tolerated and biologically active in leukopenic patients with AIDS. Strategies to increase the number and function of circulating leukocytes may reduce the morbidity and mortality of infections in these and other patients with leukopenia.
P431 BRAF AND FHIT EXPRESSION IN HCV RELATED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA AND THEIR ASSOCIATION WITH PROGNOSTIC ANATOMOPATHOLOGICAL FEATURES
Authors: P.V.T. Vidigal, P.P. Garcia, F.M.F. Osório, C.A. Couto, P.A.S. do Carmo, L.A.C. de Marco
Journal: Journal of Hepatology (2014)
DIABETES MELLITUS IS A CARDIOVASCULAR DISEASE (CVD) RISK EQUIVALENT FOR PERIPHERAL ARTERIAL DISEASE AND CAROTID ARTERY STENOSIS
Authors: Jonathan Newman, Jeffrey Berger, Caron Rockman, Yu Guo, Howard Weintraub, Arthur Schwartzbard, Mikhail Kosiborod, Mark Adelman
Journal: Journal of the American College of Cardiology (2016)
CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL
Authors: Ilaria Cavallari, Ravi Patel, Deepak Bhatt, Philippe Steg, Lawrence Leiter, Darren McGuire, Ofri Mosenzon, Estella Kanevsky, Kyungah Im, Itamar Raz, Eugene Braunwald, Benjamin Scirica
Journal: Journal of the American College of Cardiology (2016)
Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon Gamma
Authors: Roberto Badaro, Ernesto Falcoff, Fernando S. Badaro, Edgar M. Carvalho, Diana Pedral-Sampaio, Aldina Barral, Jose S. Carvalho, Manoel Barral-Netto, Maud Brandely, Luciana Silva, Jose C. Bina, Rodolfo Teixeira, Rebeca Falcoff, Heonir Rocha, John L. Ho, Warren D. Johnson
Journal: New England Journal of Medicine (1990)

Acute visceral leishmaniasis is associated with an antigen-specific immunosuppression of mononuclear cells as evidenced by defective in vitro production of interferon gamma. We evaluated treatment with recombinant human interferon gamma in combination with conventional pentavalent antimony therapy in patients with visceral leishmaniasis.
AB0734 Prevalence and co-occurrence of autoantibodies in blood donors
Authors: W. Jung, J. Prüßmann, A. Recke, K. Rentzsch, D. Juhl, R. Henschler, S. Müller, P. Lamprecht, E. Schmidt, E. Csernok, S. Görg, W. Stöcker, D. Zillikens, S. Ibrahim, R. Ludwig
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Incidence of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis, has continuously increased over the past decades [1]. Different autoimmune diseases seem to co-occur at greater than expected rates [2] and patients are prone to develop autoantibodies targeting antigens apparently unrelated to the underlying autoimmune disease. Autoantibodies can be found prior to the clinical onset of some autoimmune diseases and may be also detected in healthy individuals [3], whereas it is not clear if different autoantibodies co-occur in healthy individuals. <h3>Objectives</h3> To address this issue, prevalence of different autoantibodies was determined in healthy blood donors and tested for possible co-occurrence. <h3>Methods</h3> 5,455 blood donors were assayed and validated for presence of antinuclear antibodies (ANA) showing a SLE-associated immunofluorescence (IF) pattern and antigen specificity was determined by immunoblotting. To establish an independent control group, antibodies associated with rheumatoid arthritis (anti-CCP), autoimmune thyroiditis (anti-TPO), pernicious anemia (anti-PCA), bullous pemphigoid (anti-BP180/BP230), pemphigus (anti-Dsg1/3) and granulomatosis with polyangiitis (ANCA) as well as ANA were detected in additional 999 and 369 (TPO, PCA) blood samples, respectively. All validated ANA positive samples were also screened for these antibodies. <h3>Results</h3> ANA prevalence amounted to 5.62% (titer 1:100), 3.66% (1:320), 1.53% (1:1,000), 0.17% (1:3,200) and 0.02% (1:10,000). At least one Ab against SLE-specific antigens was detected in 77 (1.19%) samples, and frequency of detection correlated with increasing titers. Anti-CCP antibodies were detected in 1.3%, anti-TPO in 4.6%, anti-PCA in 1.1%, anti-BP180/BP230 in 0.6%, anti-Dsg1/3 in 0.1%, and ANCA in 0.3% of samples. Prevalence of anti-CCP (OR 3.2), anti-TPO (OR 2.4) and anti-Dsg1/3 antibodies (OR inf.) was significantly higher in ANA positive samples. <h3>Conclusions</h3> Our results demonstrate co-occurrence of ANA with autoantibodies to distinct antigens apparently unrelated to SLE in healthy blood donors, suggesting a common control of natural autoantibody production. Some antibodies like ANCA did not show this correlation, indicating that additional antigen dependent, immunogenetic and/or environmental factors could play a role in triggering their production. <h3>References</h3> NEJM 347:911. Journal of Autoimmunity 33(3-4):197. NEJM 349:1526. <h3>Disclosure of Interest</h3> None Declared
Diffuse Uptake of Tc-99m Tin Colloid in Extramedullary Hematopoiesis of the Lungs
Authors: T. FIKRET ÇERMIK, BURHAN TURGUT, AZIZ GULTEKIN, BİLGE ÇAKIR, ŞAKIR BERKARDA
Journal: Clinical Nuclear Medicine (2003)

ÇERMIK, T. FIKRET M.D.; TURGUT, BURHAN M.D.; GULTEKIN, AZIZ M.D.; ÇAKIR, BİLGE M.D.; BERKARDA, ŞAKIR M.D. Author Information